PILLAR RESEARCH

Pillar Research Pty Ltd
info@pillarresearch.com.au
pillarresearch.com.au

CERTIFICATE OF ANALYSIS

Compound	GHK-Cu
Pack size	Multi-dose
Batch identifier	PR-GHK-2604-001
Manufacturing date	2026-04-10
Testing date	2026-04-18
Testing laboratory	Independent third-party Australian laboratory

1. HPLC PURITY (REVERSED-PHASE, UV 220 NM)

Method: Reversed-phase high-performance liquid chromatography on a C18 column. Mobile phase: gradient acetonitrile in water with 0.1% trifluoroacetic acid. Detection at 220 nm. Purity reported as percent area under main peak relative to total integrated area.



Result	**99.0% (≥ 98% specification)**

2. MASS SPECTROMETRY (IDENTITY)

Method	Electrospray ionisation mass spectrometry (ESI-MS)
Molecular formula	C14H22CuN6O4
Theoretical mass	401.91 Da
Observed mass	401.90 Da
Result	**Identity confirmed**

3. ENDOTOXIN (LAL ASSAY)

Method	Limulus amoebocyte lysate (LAL) chromogenic assay
Result	**0.26 EU/mg (low-endotoxin specification)**

SPECIMEN — NOT FOR DISPA

4. STORAGE AND HANDLING

Store lyophilised (unreconstituted) at 2–8 °C. Protect from light and moisture. Avoid repeated freeze–thaw cycles after reconstitution. Refer to the Pillar Research reconstitution and storage guide for full handling procedure.

REGULATORY STATUS

This compound is supplied for in vitro laboratory and educational research only. It is not listed on the Australian Register of Therapeutic Goods (ARTG) and is not a therapeutic good under the Therapeutic Goods Act 1989 (Cth). Not for human or animal consumption, therapeutic use, or diagnostic procedures. Research Use Only (RUO).

Released by
QA Officer, Pillar Research
Date: 2026-04-30

Document control
Document: COA-GHK-CU
Version: 1.0

CIMEN — NOT FOR DISPA